Latest News

Business transformation services company Genpact (NYSE:G) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.4% year on year to $1.21 billion. On the other hand, next quarter’s revenue guidance of $1.22 billion was less impressive, coming in 2.3% below analysts’ estimates. Its non-GAAP profit of $0.84 per share was 5.8% above analysts’ consensus estimates.

Telecom software provider Amdocs (NASDAQ:DOX) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 9.4% year on year to $1.13 billion. The company expects next quarter’s revenue to be around $1.13 billion, close to analysts’ estimates. Its non-GAAP profit of $1.78 per share was 4.5% above analysts’ consensus estimates.

Performance marketing company QuinStreet (NASDAQ:QNST) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 60.1% year on year to $269.8 million. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.

Virtual events software company (NYSE:ONTF) announced better-than-expected revenue in Q1 CY2025, but sales fell by 7.9% year on year to $34.73 million. On the other hand, next quarter’s revenue guidance of $34.8 million was less impressive, coming in 0.7% below analysts’ estimates. Its non-GAAP loss of $0.01 per share was $0.01 above analysts’ consensus estimates.

Residential solar energy company Sunrun (NASDAQ:RUN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.1% year on year to $504.3 million. Its GAAP profit of $0.20 per share was significantly above analysts’ consensus estimates.

Beverage company Zevia (NYSE:ZVIA) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2% year on year to $38.02 million. The company expects the full year’s revenue to be around $160.5 million, close to analysts’ estimates. Its GAAP loss of $0.08 per share was 31% above analysts’ consensus estimates.

Industrial distributor DXP Enterprises (NASDAQ:DXPE) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 15.5% year on year to $476.6 million. Its non-GAAP profit of $1.26 per share was 5% above analysts’ consensus estimates.

Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $825 million at the midpoint. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.

Industrial construction and maintenance company Matrix Service (NASDAQ:MTRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 20.6% year on year to $200.2 million. The company’s full-year revenue guidance of $785 million at the midpoint came in 8.1% below analysts’ estimates. Its non-GAAP loss of $0.12 per share was significantly below analysts’ consensus estimates.

Payment technology company Crane NXT (NYSE:CXT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 5.3% year on year to $330.3 million. Its non-GAAP profit of $0.54 per share was 4.9% above analysts’ consensus estimates.

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74 per share was 7.6% above analysts’ consensus estimates.

Online used car auction platform ACV Auctions (NASDAQ:ACVA) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 25.4% year on year to $182.7 million. The company expects next quarter’s revenue to be around $195.5 million, close to analysts’ estimates. Its GAAP loss of $0.09 per share was 22.4% above analysts’ consensus estimates.

Refrigerant services company Hudson Technologies (NASDAQ:HDSN) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 15.2% year on year to $55.34 million. Its GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.

Outpatient physical therapy provider U.S. Physical Therapy (NYSE:USPH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 18.1% year on year to $183.8 million. Its non-GAAP profit of $0.48 per share was 6.2% above analysts’ consensus estimates.

Aerospace and defense company AerSale (NASDAQ:ASLE) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 27.4% year on year to $65.78 million. Its non-GAAP loss of $0.05 per share was significantly below analysts’ consensus estimates.

Shipping and mailing solutions provider Pitney Bowes (NYSE:PBI) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 40.6% year on year to $493.4 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.98 billion at the midpoint. Its non-GAAP profit of $0.33 per share was 22.2% above analysts’ consensus estimates.

Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.3% year on year to $79.41 million. On the other hand, next quarter’s revenue guidance of $80.5 million was less impressive, coming in 3.1% below analysts’ estimates. Its non-GAAP profit of $0.01 per share was in line with analysts’ consensus estimates.

Online real estate marketplace Zillow (NASDAQ:ZG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 13% year on year to $598 million. Its GAAP profit of $0.03 per share was significantly above analysts’ consensus estimates.

Environmental engineering firm Tetra Tech (NASDAQ:TTEK) announced better-than-expected revenue in Q1 CY2025, with sales up 4.9% year on year to $1.10 billion. On top of that, next quarter’s revenue guidance ($1.15 billion at the midpoint) was surprisingly good and 4.2% above what analysts were expecting. Its GAAP profit of $0.02 per share was 93.4% below analysts’ consensus estimates.

Energy recovery device manufacturer Energy Recovery (NASDAQ:ERII) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 33.3% year on year to $8.07 million. Its non-GAAP loss of $0.13 per share was significantly below analysts’ consensus estimates.

Medical lens company STAAR Surgical (NASDAQ:STAA) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 44.9% year on year to $42.59 million. Its GAAP loss of $1.10 per share was 65.2% below analysts’ consensus estimates.